

Name Robert Zeiser**Institution:**

Department of Hematology, Oncology
and Stem Cell Transplantation
Medical Center - University of Freiburg
Hugstetterstr. 55
D-79106 Freiburg

Contact:

Phone: +49 (0)761 270-34580
E-mail: robert.zeiser@uniklinik-freiburg.de

Position:

W3 Professor, Director of the Division of Tumor Immunology, Department of Medicine I,
Center for Medicine, Medical Center - University of Freiburg

Academic education including academic degrees

1995 - 2001 Study of Medicine in Freiburg, Germany, degree: MD

Scientific graduation

2010 Habilitation in Internal Medicine, University of Freiburg
2001 Dissertation in Medicine, University of Freiburg (Dept. of Pathology)

Employment

since 2019 Director of the Division for Tumor Immunology
2013-2018 Heisenberg Professorship in Hematology and Oncology
since 2010 Senior physician, Division of Hematology, Oncology and Stem Cell
Transplantation, Medical Center – University of Freiburg
2007 - 2010 Assistant physician, Department of Hematology, Oncology and Stem Cell
Transplantation, Medical Center – University of Freiburg
2005 - 2007 Postdoctorate, Stanford University, BMT Department, USA
2001 - 2004 Internship in Internal Medicine, Department of Hematology, Oncology and Stem
Cell Transplantation, Medical Center – University of Freiburg

Awards and honours

2021 Deutscher Krebspreis (DKG)
2020 Science Award of the Berlin Brandenburgische Akademie der Wissenschaften
2019 Paul Martini Award (Paul Martini Gesellschaft)
2017 Richtzenhain Cancer Research Award (DKFZ)
2016 ERC Consolidator grant (EU)
2015 Jon van Rood Award (European Society for Blood and Marrow Transplantation)
2014 Artur Pappenheim Award (Deutsche Gesellschaft für Hämatologie und Onkologie)
2013 Heisenberg Professorship (Deutsche Forschungsgemeinschaft)
2011 Theodor Frerichs Award (Deutsche Gesellschaft für Innere Medizin)
2007 BBMT Editorial award for the best publication in 2007 (ASBMT)
2006 Scholar Award (American Society of Hematology)

Scientific activities:

Since 2021 Speaker of the SFB 1479 Oncogene driven Immune escape
Since 2018 Member in the Board of Directors of SFB1160
Since 2017 Member in the Board of Directors of TRR 167
Since 2016 Section Editor of the Journal *Blood* (American Society of Hematology)
Since 2014 Deputy Director of the SFB 850

Reviewer for: Science, Nature Medicine, Nature Immunology, New England Journal of Medicine, Lancet

Most important publications

1. **Zeiser R**, (...) Locatelli, F. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. **New England Journal of Medicine**, 385(3):228-238, 2021
2. **Zeiser R**, (...) Socié, G. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. **New England Journal of Medicine**, 382(19):1800-1810, 2020
3. Prestipino A, (...) **Zeiser R**. Oncogenic JAK2V617F causes PD-L1 expression mediating immune-escape in myeloproliferative neoplasms. **Science Translational Medicine** 10 (429), 2018
4. Mathew NR, (...) **Zeiser R**. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD mutant leukemia cells. **Nature Medicine** 24: 282-291, 2018
5. Schwab L, (...) **Zeiser R**. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance GvHD via tissue damage. **Nature Medicine** 20: 648-54, 2014
6. Wilhelm K, (...) **Zeiser R**. Graft-versus-host disease is enhanced by extracellular ATP activating P2X(7)R. **Nature Medicine** 12, 1434-1438, 2010